By Colin Kellaher
Medical-technology company Teleflex said it plans to spin off its urology, acute-care and OEM businesses into an independent, publicly traded company.
Teleflex on Thursday said the remaining company, consisting of its vascular access, interventional and surgical businesses, will focus on high-growth, primarily hospital-focused emergent end markets.
The Wayne, Pa., company said it expect to complete the tax-free spinoff by mid-2026.
Teleflex said it expects the remaining company, with pro-forma 2024 revenue of about $2.1 billion, to generate constant-currency revenue growth topping 6%. The company said the spinoff had about $1.4 billion in revenue in 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2025 07:42 ET (12:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。